Global Myasthenia Gravis Drugs Market 2017-2021
- SKU ID : TNV-IRTNTR11520 10436766
- |
- Publishing Date: 12-Jan-2017
- |
- Region: Global
- |
- No. of pages: 73
About Myasthenia Gravis Drugs
Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.
Technavio’s analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals
Other prominent vendors
• Alexion Pharmaceuticals
• Catalyst Pharmaceuticals
• CSL
• Curavac
• Cytokinetics
• Galencia
• GlaxoSmithKline
• Lupin Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Novartis
Market driver
• Approval of novel monoclonal antibodies
• For a full, detailed list, view our report
Market challenge
• Limited availability of approved drugs
• For a full, detailed list, view our report
Market trend
• Emergence of new entrants
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.
Technavio’s analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals
Other prominent vendors
• Alexion Pharmaceuticals
• Catalyst Pharmaceuticals
• CSL
• Curavac
• Cytokinetics
• Galencia
• GlaxoSmithKline
• Lupin Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Novartis
Market driver
• Approval of novel monoclonal antibodies
• For a full, detailed list, view our report
Market challenge
• Limited availability of approved drugs
• For a full, detailed list, view our report
Market trend
• Emergence of new entrants
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
